April 25th 2024
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.
April 24th 2024
Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.
April 23rd 2024
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
April 22nd 2024
Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.
April 18th 2024
Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.
April 17th 2024
Abdulrahman Sinno, MD, highlights key trials that have impacted the treatment paradigm in endometrial and ovarian cancer throughout 2023.
April 16th 2024
Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma.
Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer.
Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.
Olutasidenib alone or administered with azacitidine was safe and clinically effective in patients with IDH1-mutated myelodysplastic syndrome.
April 14th 2024
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.
April 11th 2024
The galectin-9–targeted monoclonal antibody LYT-200 received FDA fast track designation for recurrent/metastatic head and neck squamous cell cancer.
Abdulrahman Sinno, MD, discusses the paradigm shift from a histology-based to molecular-based understanding of endometrial cancer and its impact on treatment outcomes.
April 10th 2024
Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.
LSTA1 has been granted orphan drug designation by the FDA for the treatment of patients with osteosarcoma.
A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.
April 8th 2024
Administration of atezolizumab after definitive local therapy did not improve EFS or OS in patients with head and neck squamous cell carcinoma.
The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.
April 5th 2024
Durvalumab monotherapy showed clinical benefit in limited-stage small cell lung cancer, according to data from the phase 3 ADRIATIC trial.